Talk to your healthcare provider about any side effect that bothers you, becomes severe, or does not go away
Individual experiences with medications may vary
Lys(9) for Glu(9) substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(936)amide and exendin (939)
Petersen N, Reimann F, van Es JH, van den Berg BM, Kroone C, Pais R, et al
Tracking the right metrics during your transition from tirzepatide to retatrutide provides objective data about whether the switch is working, whether your dose needs adjustment, and whether you are experiencing the full benefit of triple receptor agonism
However, researchers have noted that the "GIP-heavy" profile of Retatrutide and Tirzepatide may actually blunt some of the more severe emetic effects seen with pure GLP-1 agonists